PTCT
HealthcarePTC Therapeutics, Inc. · Biotechnology · $6B
What is PTC Therapeutics, Inc.?
PTC Therapeutics is a biopharmaceutical company dedicated to discovering and commercializing treatments for rare diseases. Headquartered in South Plainfield, New Jersey, the company has built a portfolio spanning multiple therapeutic areas with a focus on patients who have limited treatment options.
PTC Therapeutics generates revenue by developing and commercializing medicines for rare disorders. Its commercial products address conditions such as Duchenne muscular dystrophy and spinal muscular atrophy across markets including the United States, European Economic Area, Brazil, and Latin America. The company also advances an internal research pipeline — including a splicing platform targeting Huntington's disease — and maintains collaborations with larger pharmaceutical partners to expand its reach and accelerate drug discovery.
PTC Therapeutics was incorporated in 1998 and operates from its headquarters in South Plainfield, New Jersey.
- Translarna — treatment for nonsense mutation Duchenne muscular dystrophy
- Emflaza — corticosteroid therapy for Duchenne muscular dystrophy
- Evrysdi — spinal muscular atrophy treatment commercialized in Brazil
- Tegsedi and Waylivra — rare disease therapies in Latin America and the Caribbean
- PTC518 — investigational splicing therapy for Huntington's disease
Is PTCT a Good Stock to Buy?
UQS Score rates PTCT as Good overall, reflecting a balanced profile across its five analytical pillars.
The Quality and Risk pillars both register as Strong, suggesting the company demonstrates above-average financial discipline and a manageable risk profile relative to its rare-disease peers. The Valuation pillar also reads as Good, meaning the stock does not appear significantly stretched on a fundamental basis.
The Moat and Growth pillars both sit at Neutral, indicating that competitive differentiation and near-term expansion potential are less pronounced than in the company's strongest areas.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PTCT pay dividends?
No — PTC Therapeutics, Inc. does not currently pay a dividend.
PTCT does not currently pay a dividend. This is common among clinical-stage and growth-oriented biopharmaceutical companies, where capital is typically reinvested into research, pipeline development, and commercialization efforts rather than returned to shareholders as income. Investors in PTCT are generally seeking long-term value through pipeline advancement rather than current yield.
When does PTCT report earnings?
PTC Therapeutics reports earnings on a quarterly cadence, consistent with standard practice for US-listed public companies.
Quarterly results for rare-disease biotechs like PTC Therapeutics tend to reflect product revenue trends across their commercial markets, pipeline milestone updates, and operating expense management. Investors typically watch for changes in product uptake across geographies and progress on clinical programs.
For the most recent quarter's results and upcoming reporting dates, visit PTC Therapeutics' investor relations page directly.
PTCT Price History
+79.9% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in PTC Therapeutics, Inc.?
Based on PTC Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PTCT Long-term Outlook
With Growth and Moat both rated Neutral, PTC Therapeutics' near-term trajectory appears measured rather than accelerating. The Strong Risk rating suggests the company is managing its operational and financial exposures relatively well for a rare-disease biotech. The combination of a Good Valuation and Strong Quality profile indicates the business has a degree of fundamental stability, though meaningful upside likely depends on pipeline execution and geographic expansion of existing products.
Growth drivers
- Continued geographic expansion of commercial rare-disease products into new markets
- Advancement of the PTC518 Huntington's disease program through clinical milestones
- Collaboration revenues and milestone payments from pharmaceutical partnerships
Key risks
- Pipeline clinical trial failures or regulatory setbacks in key markets
- Concentration risk from dependence on a small number of approved products
- Competitive pressure in rare-disease therapeutic areas from larger, better-resourced biotechs
PTCT vs Peers
PTC Therapeutics operates in a competitive rare-disease and specialty biopharmaceutical landscape alongside companies pursuing distinct scientific and commercial strategies.
Caris focuses on molecular profiling and precision oncology diagnostics, approaching rare and complex diseases through a data-driven testing platform rather than drug development.
Immunovant is developing FcRn inhibitor therapies targeting autoimmune diseases, competing for rare-disease patient populations with a different mechanistic approach than PTC's splicing and gene-expression platforms.
Cogent concentrates on precision therapies for genomically defined cancers and rare diseases, with a targeted kinase inhibitor strategy that differs from PTC's RNA-based and splicing-focused pipeline.
Frequently Asked Questions
What does PTC Therapeutics do?
PTC Therapeutics discovers, develops, and commercializes medicines for patients with rare disorders. Its approved products treat conditions including Duchenne muscular dystrophy and spinal muscular atrophy across markets in the US, Europe, Brazil, and Latin America. The company also maintains an active research pipeline, including a splicing platform targeting Huntington's disease.
Does PTCT pay dividends?
PTC Therapeutics does not currently pay a dividend. Like many biopharmaceutical companies focused on rare diseases, the company reinvests available capital into research, clinical development, and commercialization activities rather than distributing cash to shareholders.
When does PTCT report earnings?
PTC Therapeutics follows a standard quarterly earnings reporting schedule for US-listed companies. For exact upcoming report dates and recent financial results, investors should check the company's official investor relations page, as specific dates are subject to change.
Is PTCT a good stock to buy?
UQS Score rates PTCT as Good overall. The Quality and Risk pillars are both Strong, while Valuation reads as Good. Growth and Moat are Neutral, suggesting the investment case depends on pipeline progress. The full pillar breakdown is available to Pro members on UQS Score.
Is PTCT overvalued?
The UQS Valuation pillar for PTCT is rated Good, suggesting the stock does not appear significantly overpriced on a fundamental basis relative to its profile. Whether it represents value for a specific investor depends on individual risk tolerance and time horizon. View the complete valuation analysis with a Pro membership.
How does PTCT compare to its competitors?
PTC Therapeutics competes in the rare-disease space alongside companies like Immunovant and Cogent Biosciences, each pursuing different scientific platforms. PTC's combination of commercial products and an active pipeline distinguishes it from earlier-stage peers. The UQS competitor comparison tool lets Pro members benchmark pillar scores side by side.
What is PTCT's market cap bracket?
PTC Therapeutics is classified as a mid-cap company. This places it in a segment that typically offers more established operations than small-cap biotechs while retaining meaningful growth potential compared to large-cap pharmaceutical companies.
Who founded PTC Therapeutics?
PTC Therapeutics was founded by scientists with backgrounds in RNA biology and rare-disease research. The company was incorporated in 1998. For detailed founding history and leadership background, the company's official website and public filings are the most reliable sources.
Is PTCT a long-term quality investment?
From a quality indicator standpoint, PTCT's Strong Quality and Strong Risk pillar ratings suggest a degree of operational and financial discipline that supports a longer-term view. However, the Neutral Growth and Moat ratings mean long-term outcomes will depend heavily on pipeline execution and competitive positioning in rare-disease markets.
What is the main competitive advantage of PTC Therapeutics?
PTC Therapeutics has built expertise in RNA biology and splicing science, enabling it to pursue disease targets that are difficult for conventional drug developers to address. Its established commercial presence in rare-disease markets and pharmaceutical collaborations — including with Roche — provide additional differentiation, though the UQS Moat pillar currently rates this advantage as Neutral.
What sector does PTCT belong to?
PTCT is classified in the Healthcare sector, specifically within the biopharmaceutical and rare-disease subsegment. Investors can explore other [top Healthcare stocks](/sector/healthcare) on UQS Score to compare quality profiles across the sector.
Unlock Full PTCT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access detailed financial metrics and trend data
- ✓Compare PTCT side-by-side with rare-disease peers
- ✓Track Quality, Risk, and Valuation changes over time
- ✓Explore the complete analyst-style fundamental breakdown
Pro Analysis
PTCT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 45.6 | 33.3 | 47.0 | 50.0 | 41.8 | 61.6 | -19.2 |
| May 6, 2026 | 64.8 | 83.3 | 47.0 | 50.0 | 82.1 | 66.0 | 0.0 |
| May 3, 2026 | 64.8 | 83.3 | 47.0 | 50.0 | 82.1 | 66.3 | 0.0 |
| Apr 28, 2026 | 64.8 | 83.3 | 47.0 | 50.0 | 82.1 | 66.0 | +0.3 |
| Apr 26, 2026 | 64.5 | 83.3 | 47.0 | 50.0 | 82.1 | 64.0 | +0.1 |
| Apr 19, 2026 | 64.4 | 83.3 | 47.0 | 50.0 | 82.1 | 63.7 | -0.1 |
| Apr 18, 2026 | 64.5 | 83.3 | 47.0 | 50.0 | 82.1 | 63.9 | +1.7 |
| Apr 14, 2026 | 62.8 | 83.3 | 47.0 | 50.0 | 82.1 | 52.8 | 0.0 |
| Apr 12, 2026 | 62.8 | 83.3 | 47.0 | 50.0 | 82.1 | 53.0 | 0.0 |
| Apr 5, 2026 | 62.8 | 83.3 | 47.0 | 50.0 | 82.1 | 52.9 | 0.0 |
PTCT — Pillar Breakdown
Quality
— 33.3/100 (25%)PTC Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 50.0/100 (20%)PTC Therapeutics, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 41.8/100 (15%)PTC Therapeutics, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 61.9/100 (15%)PTC Therapeutics, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Moat
— 47/100 (25%)PTC Therapeutics, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PTCT.
Score Composition
Financial Data
More Stock Analysis
How is the PTCT UQS Score Calculated?
The UQS (Unified Quality Score) for PTC Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses PTC Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether PTC Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.